Added to YB: 2025-10-16
Pitch date: 2025-10-14
MDXH [bullish]
MDxHealth SA
-1.94%
current return
Author Info
Kubang Pasu Capital is an experienced investor with over 6 years in equity research and market analysis. Focused on identifying undervalued opportunities and building long-term value through disciplined investment strategies. Sign up for the newsletter.
Company Info
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
Market Cap
$207.9M
Pitch Price
$4.12
Price Target
8.24 (+104%)
Dividend
N/A
EV/EBITDA
-26.80
P/E
-5.37
EV/Sales
2.62
Sector
Biotechnology
Category
value
MDxHealth (NASDAQ: MDXH) trading at 2.2x EV/S while on track to growth & profitability
MDXH: Precision diagnostics for prostate cancer nearing profitability. 2024 rev $90M (+28% YoY), targeting $108-110M in 2025 with +ve adj EBITDA Q2. ExoDx acquisition adds $20M+ 2026 revenue. Trades 2.2-2.6x EV/sales vs peers at 6-11x. $8.24 price target (~101% upside). Risk: liquidity concerns.
Read full article (3 min)